March 29, 2017 – Tel Aviv, Israel, and Danvers, MA – MedyMatch Technology, Ltd. and Samsung NeuroLogica Corporation, the healthcare subsidiary of Samsung Electronics Co., Ltd., today announced a collaboration to integrate artificial intelligence (A.I.) clinical decision support applications with Samsung NeuroLogica’s medical imaging hardware in the acute care marketplace. This collaboration will create support tools that provide a second read capability to help caregivers quickly and accurately assess patients in prehospital environments.
The first focus area will be in the enhancement of stroke assessment, specifically, with the integration of MedyMatch’s A.I. technologies into the mobile stroke unit (MSU), a specialized ambulance or other emergency vehicles that is equipped with a Samsung NeuroLogica CereTom® CT (computed tomography) scanner. The mobile unit with diagnostic CT imaging capabilities is designed to allow the team onboard to quickly assess whether a patient is having a stroke caused by a blood clot or hemorrhage. The very first step in patient assessment is to rule out the presence of a brain bleed, and this is where MedyMatch’s technology will be utilized pending regulatory approval to provide decision support. Since “Time Lost is Brain Lost,” rapid patient assessment will allow caregivers to move quickly down the most appropriate treatment path, potentially even while in transit to the hospital.
“We are on the threshold of the next evolutionary step in Imaging”, said Gene Saragnese, Chairman & CEO of MedyMatch, “Imaging technological development has been historically focused on providing clinicians the best possible image, optimizing spatial and temporal resolution, coverage and dose; however, MedyMatch’s artificial intelligence applications will leap this paradigm forward, enabling Imagers such as CT to provide clinical answers and not just images. Creating a truly intelligent imaging machine to assist physicians every day.”
A stroke occurs when blood flow to the brain is interrupted by a blockage or a rupture in an artery, depriving brain tissue of oxygen. Stroke is the fourth leading cause of death in the United States and a leading cause of disability. According to the CDC, close to 800,000 Americans suffer a stroke each year. Most suffer ischemic stroke, which occurs when blood flow to the brain is obstructed by a clot in a blood vessel. Fortunately, ischemic stroke can be treated effectively with a tissue plasminogen activator (tPA), a drug that if administered within three hours of the first signs of stroke dissolves a clot to improve blood flow back to the affected part of the brain. Unfortunately, it can take an hour after a stroke patient arrives in the emergency department to receive treatment because of the time needed to determine which kind of stroke the patient is having.
“Technology that can assist the physicians in recognizing brain bleeds more quickly, will lead to faster decision making for the patient and better outcomes,” said Dr. Peter Rasmussen, Medical Director of Cleveland Clinic’s Distance Health Program. “Emergency treatment is needed to recognize and treat brain bleeds as quickly as possible and is critical in ensuring minimal damage.”
“This is just one example of how Intelligent imaging can have a positive impact on a stroke or trauma patient and provide a whole new level of care by bringing “A.I. to the curbside”, said Robert Mehler, Chief Operating Officer of MedyMatch. “MedyMatch envisions that medical imaging devices will be A.I. enabled with decision support to assist the physician in patient care, increase the speed in which patient assessment can be performed, and optimize the clinical workflow.”
“Samsung is committed to bringing innovative technology to the marketplace to improve patient outcomes. Our CereTom equipped Mobile Stroke Units are at the forefront of that commitment,” said Phillip Sullivan, President, and Chief Executive Officer, Samsung NeuroLogica. “We are seeing worldwide demand and implementation of our Mobile Stroke Units, with new installations in New York, Trenton, Chicago, Bangkok, Alberta, India, and Germany. Our collaboration with MedyMatch is one more step forward in advanced technology to support better treatment of stroke.”
The portable X-ray and CT scan device market growth is expected to grow approximately 7.6% CAGR to 2020, reaching $8.41B, and MedyMatch is at the forefront of enabling this industry growth.
About MedyMatch Technology
MedyMatch is bringing to market a new category of medical solutions. MedyMatch utilizes advanced cognitive analytics and artificial intelligence to deliver real-time decision support tools to improve clinical outcomes in acute medical scenarios. The foundation of clinical discovery and value creation lies in the deep clinical understanding of how to utilize the right data (electronic medical record, medical imaging, and genomic data). The MedyMatch team of artificial intelligence, machine learning, deep learning, and algorithmic experts along with its medical and scientific advisory boards are achieving breakthroughs in standards of cost and care. To learn more, please visit www.medymatch.com.
About Samsung NeuroLogica
Samsung NeuroLogica, the healthcare subsidiary of Samsung Electronics Co., Ltd., develops, manufactures, and markets innovative imaging technologies and is committed to delivering fast, easy, and accurate diagnostic solutions to healthcare providers. Samsung NeuroLogica, the global corporate headquarters, and manufacturer of computed tomography is also the U.S. headquarters for sales, marketing, and distribution of all Samsung digital radiography and ultrasound systems. Samsung NeuroLogica’s growing portfolio of advanced medical technologies is used worldwide in leading healthcare institutions. They help providers enhance patient care, improve patient satisfaction, and increase workflow efficiency. Samsung is committed to being leaders in the field of healthcare imaging. For more information, please visit www.SamsungNeuroLogica.com.